Return to site

Emergent BioSolutions Obtains Grant to Develop Antidote Auto-Injector

Fuad El-Hibri

A graduate of Stanford University and Yale University, Fuad El-Hibri has professional experience in a number of industries, including the biopharmaceutical sphere. At present, Fuad El-Hibri serves as executive chairman of the board at Emergent BioSolutions, a global biopharmaceutical company he founded in 1998.

In July 2017, Emergent BioSolutions announced that the Medical CBRN Defense Consortium (MCDC), an initiative of the Department of Defense’s Joint Project Manager for Medical Countermeasure Systems, has awarded the company a five-year, $23 million contract to create a new multidrug auto-injector. Envisioned for both military and civilian use, the intramuscular device would be used to deliver nerve agent antidotes in case of accidental or intentional exposure.

In addition to developing the injector, Emergent BioSolutions will conduct tests to verify the quality and usability of the final product. Per the terms of the agreement, the company will also spearhead the device’s approval process with the US Food and Drug Administration.

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly